This collaboration provides clinical validation for IDEAYA's PRMT5 program and access to Roche's pan-RAS inhibitor, but with no near-term financial catalysts. Monitor for Phase 1 data readouts and potential expansion into triplet combinations. The stock may see modest positive sentiment from the partnership, but fundamental value remains tied to clinical execution.
Price Chart
Executive Summary
IDEAYA announced a clinical collaboration with Roche to evaluate its PRMT5 inhibitor IDE892 in combination with Roche's pan-RAS inhibitor RG6505 for MTAP-deleted, RAS-mutant pancreatic cancer (PDAC). IDEAYA will sponsor the trial and Roche will supply RG6505; each party retains full commercial rights to its own compounds. This is an early-stage, non-financial collaboration that validates IDEAYA's MTAP-deletion portfolio but carries no near-term revenue or milestone payments.
Key Facts
- IDEAYA entered a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) + RG6505 (pan-RAS inhibitor) in MTAP-deleted RAS-mutant PDAC.
- IDEAYA sponsors the trial; Roche supplies RG6505.
- Each party retains all commercial rights to its own compounds; no financial terms disclosed.
- MTAP deletion estimated in up to 40% of PDAC; almost all MTAP-deleted PDAC harbor RAS mutations.
- IDE892 is in Phase 1 dose escalation; combination cohorts planned in PDAC, NSCLC, and other solid tumors.
- Triplet combination with IDE397 (MAT2A inhibitor) possible upon joint approval.
Financial Impact
No financial terms disclosed; no upfront, milestone, or royalty payments mentioned.
Risk Factors
- Early-stage clinical risk — preclinical results may not translate to human efficacy.
- No financial terms disclosed; collaboration provides no near-term revenue or milestone payments.
- Dependence on Roche for drug supply and joint governance may slow trial execution.
- Competitive landscape for PRMT5 and RAS-targeted therapies is evolving.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254476 |
| Document: 0001193125-26-254476-index-headers.html | 0001193125-26-254476 |
| Document: 0001193125-26-254476-index.html | 0001193125-26-254476 |
| Document: 0001193125-26-254476.txt | 0001193125-26-254476 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.03 (+2.56%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.03 (+2.08%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.03 (−28.42%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.03 (−34.18%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.03 (−31.94%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.03 (+30.40%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.03 (+28.86%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.03 (+28.86%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.03 (+12.84%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.03 (+19.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access